E
LYEL icon

Ergoteles’s Lyell Immunopharma LYEL Stock Holding History

Ergoteles’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,117
Closed -$71K – 511
2023
Q2 		$71K Buy
+1,117
New +$61.8K ﹤0.01% 936
2022
Q1 		– Sell
-50,421
Closed -$7.8M – 1463
2021
Q4 		$7.8M Buy
+50,421
New +$11.2M 0.3% 74

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

Ergoteles's LYEL Position: Q3 2023 in Review

Ergoteles sold out of Lyell Immunopharma (LYEL) in Q3 2023, closing a stake of 1,117 shares — an estimated $71K sold.

Ergoteles first reported a position in LYEL in Q4 2021 and held it in 2 quarters. The position peaked at $7.8M in Q4 2021. 106 funds tracked by Wall St. Rank hold LYEL as of Q3 2023.

  • Ergoteles reported no remaining Lyell Immunopharma position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 1,117 Lyell Immunopharma shares in Q3 2023, an estimated $71K.
  • Ergoteles first reported a position in Lyell Immunopharma in Q4 2021 and held it in 2 quarters.
  • Ergoteles's Lyell Immunopharma position peaked at $7.8M in Q4 2021.
  • 106 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.